Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04592536 | A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects | PHASE1 | COMPLETED | 56 | — | — | Oct 1, 2020 | Dec 1, 2021 | Jan 10, 2022 | - | — |
| Name | Type | Description |
|---|---|---|
| CVL-865 High dose | DRUG | High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day) |
| Alprazolam 1mg XR | DRUG | Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day) |
| Placebo | DRUG | Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day) |
| CVL-865 low dose | DRUG | Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day) |